Antiandrogens: all 479 studies that test it
Page 1 of 5. Open to participants first (92), then studies with results posted, then the rest; newest registration first within each.
- Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate CancerNot yet recruitingNCT07907653Phase 2
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNot yet recruitingNCT07852195Phase 2/3
- A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingNCT07783282Phase 1
- Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.Not yet recruitingNCT07730151Phase 2
- Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.RecruitingNCT07717268Phase 2
- Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA)Not yet recruitingNCT07714616Phase 3
- Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate CancerNot yet recruitingNCT07683013Phase 1
- 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical TrialNot yet recruitingNCT07677566Phase 4
- Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScoreRecruitingNCT07617272Phase 2
- Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate CancerNot yet recruitingNCT07593079Phase 2
- Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical StudyNot yet recruitingNCT07516704Early Phase 1
- Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPCRecruitingNCT07503379Phase 2
- Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate CancerNot yet recruitingNCT07476677Phase 2
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTRecruitingNCT07455903Phase 2
- A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.RecruitingNCT07450599Phase 2
- Androgen-responsive POSLUMA-guided Intra-prostatic BoostRecruitingNCT07393867Phase 2
- Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesRecruitingNCT07340541Phase 2
- Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019Not yet recruitingNCT07282197Phase 2
- Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate CancerRecruitingNCT07260435Phase 3
- A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruitingNCT07226986Phase 1/2
- Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)RecruitingNCT07210086Phase 2
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)RecruitingNCT07190300Phase 1/2
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseRecruitingNCT07142551Phase 2
- A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's DiseaseRecruitingNCT07117851Phase 2
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)RecruitingNCT07103018Phase 1
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate CancerRecruitingNCT07027124Phase 2
- Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCRecruitingNCT07016399Phase 2
- Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne VulgarisRecruitingNCT06905210Phase 3
- Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPCNot yet recruitingNCT06768255Phase 3
- Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PETRecruitingNCT06758882Phase 2
- Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCCNot yet recruitingNCT06694350Phase 2
- Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.Not yet recruitingNCT06660862Phase 4
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingNCT06632977Phase 2
- Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of RelapseRecruitingNCT06625970Phase 3
- Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingNCT06616155Phase 1/2
- Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate CancerRecruitingNCT06582628Phase 2
- Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate CancerRecruitingNCT06575257Phase 2
- Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL TrialRecruitingNCT06499870Phase 2
- Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)RecruitingNCT06401980Phase 2
- Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast CancerRecruitingNCT06365788Phase 2
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersRecruitingNCT06282588Phase 2/3
- PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.RecruitingNCT06274047Phase 3
- Enzalutamide Implants (Enolen) in Patients With Prostate CancerRecruitingNCT06257693Phase 1
- Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT06236139Phase 1/2
- Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCCRecruitingNCT06222593Phase 1/2
- SNV1521 in Participants With Advanced Solid TumorsRecruitingNCT06220864Phase 1
- Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate CancerNot yet recruitingNCT06198387Not applicable
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerRecruitingNCT06190899Phase 1/2
- Intermittent Darolutamide Treatment in the Triple Therapy of mHSPCRecruitingNCT06177015Phase 3
- Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate CancerRecruitingNCT06173362Phase 2
- Relugolix + Enzalutamide Study in High-Risk Prostate CancerRecruitingNCT06130995Phase 1
- Combination Study of Antibiotics With Enzalutamide (PROMIZE)RecruitingNCT06126731Phase 1/2
- A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast CancerRecruitingNCT06099769Phase 2
- Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering TherapyRecruitingNCT06096870Phase 2
- Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE TrialRecruitingNCT06067269Phase 2
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerRecruitingNCT06059118Phase 2
- A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate CancerRecruitingNCT06029036Phase 2
- An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic AdenocarcinomaNot yet recruitingNCT06015321Phase 2
- Bicalutamide Therapy in Young Women With NAFLD and PCOSRecruitingNCT05979389Phase 1
- A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate CancerRecruitingNCT05900973Phase 2
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingNCT05873192Phase 2
- Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)Not yet recruitingNCT05778097Phase 2
- Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPCRecruitingNCT05762536Phase 2
- Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone MetastasesRecruitingNCT05740488Not applicable
- Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT TreatmentNot yet recruitingNCT05717582Phase 2
- The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2Not yet recruitingNCT05647356Not applicable
- Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC StageRecruitingNCT05627752Phase 2/3
- A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder CancerRecruitingNCT05521698Phase 1
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingNCT05406999Phase 2
- A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)RecruitingNCT05348876Phase 4
- A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder CancerRecruitingNCT05327647Phase 2
- GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia PatientsRecruitingNCT05316935Phase 2/3
- Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate CancerRecruitingNCT05249712Phase 2
- TherApeutics in Early ProState Cancer (TAPS02)RecruitingNCT05191680Phase 2
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
- Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes MetastasesRecruitingNCT05116475Phase 3
- Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast CancerRecruitingNCT05095207Phase 1/2
- SRT Versus SRT+ADT in Prostate CancerRecruitingNCT05019846Phase 3
- An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate CancerRecruitingNCT04997252Not applicable
- ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)RecruitingNCT04916613Phase 3
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingNCT04812366Phase 2
- Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate CancerRecruitingNCT04641078Phase 2
- Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in JapanRecruitingNCT04601441Phase 4
- Sequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionRecruitingNCT04363164Phase 2
- Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerNot yet recruitingNCT04176081Phase 2
- National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer PatientsRecruitingNCT04086290Phase 1/2
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingNCT03903835Phase 3
- Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
- Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPRecruitingNCT03899077Phase 2
- A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).RecruitingNCT03851640Phase 3
- Signal TrAnsduction Pathway Activity Analysis in OVarian cancERRecruitingNCT03458221Phase 2/3
- Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate CancerRecruitingNCT02935205Phase 1/2
- Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsCompletedNCT06169124Phase 2Results posted
- Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyTerminatedNCT05960578Phase 2Results posted
- Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerCompletedNCT05730712Phase 2Results posted
- Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerTerminatedNCT05617885Phase 1Results posted
- A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With EnzalutamideCompletedNCT05526248Phase 2Results posted
- Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate CancerActive, not recruitingNCT05081193Phase 2Results posted
- A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.CompletedNCT05059236Phase 2Results posted
- Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate CancerTerminatedNCT04737109Phase 1/2Results posted